<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>drug accessibility &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/drug-accessibility/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 11:22:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>drug accessibility &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>China Cuts Drug Approval Lag but Reimbursement Gaps Persist for Overseas New Medicines</title>
		<link>https://bioengineer.org/china-cuts-drug-approval-lag-but-reimbursement-gaps-persist-for-overseas-new-medicines/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 11:22:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[approval lag]]></category>
		<category><![CDATA[Biologics]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[drug accessibility]]></category>
		<category><![CDATA[drug regulation]]></category>
		<category><![CDATA[ICH harmonization]]></category>
		<category><![CDATA[multi-regional clinical trials]]></category>
		<category><![CDATA[National Reimbursement Drug List]]></category>
		<category><![CDATA[NMPA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[rare disease drugs]]></category>
		<category><![CDATA[reimbursement policy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=426279</guid>

					<description><![CDATA[A 16-year analysis of 361 overseas new drugs shows China's regulatory reforms cut approval lag and reimbursement delays, but biologics, pediatric medicines, and conditionally approved therapies still face steep barriers to national insurance coverage.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">426279</post-id>	</item>
	</channel>
</rss>
